Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Nausea 12Vomiting 11Neoplasms 7Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Gynecologic Cancer 1Esophageal Neoplasms 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Olanzapine × Clear all
NCT06554613 2026-05-05

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Second Affiliated Hospital of Nanchang University

Phase 2 Recruiting
156 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡